Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
Researchers reported significant changes in liver, cardiovascular and diabetes markers.
Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.
NAFLD is the leading indicator of mortality among Medicare beneficiaries with hepatocellular carcinoma.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
Non-alcoholic fatty liver disease can be driven by toxin exposure.
This benefit was independent of weight control among the animals.
Instead of non-alcoholic fatty liver disease, they suggest calling it metabolic-associated fatty liver disease.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
A compound found in veggies such as broccoli, kale and Brussels sprouts may help prevent a liver condition that increases cancer risk.
Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.
Those with NAFLD or NASH and cirrhosis should undergo regular screening.
Gastrointestinal cancers conference emphasizes patient quality of life.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.